CN109641898B - 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物 - Google Patents

用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物 Download PDF

Info

Publication number
CN109641898B
CN109641898B CN201780053245.2A CN201780053245A CN109641898B CN 109641898 B CN109641898 B CN 109641898B CN 201780053245 A CN201780053245 A CN 201780053245A CN 109641898 B CN109641898 B CN 109641898B
Authority
CN
China
Prior art keywords
group
pyridin
alkoxy
mmol
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780053245.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109641898A (zh
Inventor
L.张
C.R.巴特勒
E.M.贝克
M.A.布罗尼
M.F.布朗
L.A.麦卡利斯特
E.A.拉查佩尔
A.M.吉尔伯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of CN109641898A publication Critical patent/CN109641898A/zh
Application granted granted Critical
Publication of CN109641898B publication Critical patent/CN109641898B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780053245.2A 2016-07-01 2017-06-15 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物 Active CN109641898B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662357624P 2016-07-01 2016-07-01
US62/357624 2016-07-01
US201662372421P 2016-08-09 2016-08-09
US62/372421 2016-08-09
PCT/IB2017/053565 WO2018002760A1 (en) 2016-07-01 2017-06-15 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases

Publications (2)

Publication Number Publication Date
CN109641898A CN109641898A (zh) 2019-04-16
CN109641898B true CN109641898B (zh) 2022-04-08

Family

ID=59215839

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780053245.2A Active CN109641898B (zh) 2016-07-01 2017-06-15 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物

Country Status (20)

Country Link
US (5) US10604519B2 (enExample)
EP (2) EP3872078A1 (enExample)
JP (1) JP7046018B2 (enExample)
KR (1) KR102470497B1 (enExample)
CN (1) CN109641898B (enExample)
AU (1) AU2017286868B2 (enExample)
CA (1) CA2972070A1 (enExample)
DK (1) DK3478679T3 (enExample)
ES (1) ES2878160T3 (enExample)
HU (1) HUE054857T2 (enExample)
IL (1) IL263912B (enExample)
MX (1) MX386258B (enExample)
PH (1) PH12019500004A1 (enExample)
PL (1) PL3478679T3 (enExample)
PT (1) PT3478679T (enExample)
SG (1) SG11201811712QA (enExample)
TW (1) TWI736642B (enExample)
UY (1) UY37311A (enExample)
WO (1) WO2018002760A1 (enExample)
ZA (1) ZA201900519B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018226545A1 (en) * 2017-06-09 2018-12-13 Merck Sharp & Dohme Corp. Azabicyclo[4.1.0]heptane allosteric modulators of the m4 muscarinic acetylcholine receptor
FI3642202T3 (fi) * 2017-06-22 2023-03-01 Dihydro-pyrrolo-pyridiinijohdannaisia
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP4061813B1 (en) 2019-11-22 2025-06-04 F. Hoffmann-La Roche AG Pyrrolidine derivatives
CA3174675A1 (en) * 2020-04-29 2021-11-04 Relay Therapeutics, Inc. Pi3k.alpha. inhibitors and methods of use thereof
CN112174869B (zh) * 2020-10-12 2023-04-25 蔡霈 N-苯乙酰基-2-羟甲基吡咯烷-2-甲酰胺的制备方法及其药用用途
JP2023549738A (ja) * 2020-10-30 2023-11-29 １シーバイオ， インコーポレイテッド エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼ－１（ｅｎｐｐ１）阻害物質及びそれらの使用
WO2022235514A1 (en) * 2021-05-04 2022-11-10 Mind Medicine, Inc. Liposome delivery of psychedelics
CN120677153A (zh) * 2022-09-23 2025-09-19 赛尔维治疗有限责任公司 Emraclidine的晶型及其制备方法和用途
JP2025534061A (ja) * 2022-10-28 2025-10-09 紐欧申医薬（上海）有限公司 窒素含有複素環化合物、その薬学的に許容される塩及びその調製方法と使用
KR20250121123A (ko) 2022-12-16 2025-08-11 카루나 세러퓨틱스 인코포레이티드 치환된 테트라히드로피롤로-피리디논 화합물 및 의학적 병태를 치료하는 데 있어서의 이의 용도
CN120641421A (zh) * 2022-12-16 2025-09-12 卡鲁娜治疗学有限公司 经取代的二氢吡咯并[3,4-d]嘧啶化合物及其在治疗医学病状中的用途
WO2024130065A1 (en) * 2022-12-16 2024-06-20 Karuna Therapeutics, Inc. Substituted dihydropyrrolo[3, 4-d]pyrimidine compounds and their use in treating medical conditions
KR20250130620A (ko) * 2022-12-16 2025-09-02 카루나 세러퓨틱스 인코포레이티드 치환된 테트라하이드로피롤로-피리디논 화합물 및 의학적 병태 치료에서의 이의 용도
WO2024230794A1 (zh) * 2023-05-11 2024-11-14 中国药科大学 氮杂环丁烷衍生物、其制备方法及其医药用途
CN116693437A (zh) * 2023-06-15 2023-09-05 安徽大学 一种N-Boc-3-氮杂环丁烷乙酸的合成方法
WO2024260386A1 (zh) * 2023-06-20 2024-12-26 西藏海思科制药有限公司 毒蕈碱m4受体激动剂及其用途
WO2025055965A1 (zh) * 2023-09-13 2025-03-20 中国药科大学 氮杂环丁烷衍生物、其制备方法及其医药用途
WO2025055970A1 (zh) * 2023-09-15 2025-03-20 江苏恩华药业股份有限公司 氮杂环丁烷衍生物、其制备方法及其医药用途
WO2025083630A1 (en) 2023-10-19 2025-04-24 Suven Life Sciences Limited Heteroaromatic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)
WO2025099660A1 (en) 2023-11-10 2025-05-15 Suven Life Sciences Limited Piperidine substituted compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)
WO2025103475A1 (zh) * 2023-11-17 2025-05-22 上海翰森生物医药科技有限公司 杂环羰基类衍生物调节剂、其制备方法和应用
TW202527956A (zh) * 2023-12-07 2025-07-16 美商阿卡蒂亞藥品公司 Ｍ４陽性變構調節劑
WO2025131049A1 (en) * 2023-12-21 2025-06-26 Ignis Therapeutics (Suzhou) Limited Dihydro-pyrrolo-pyridine derivatives and uses thereof
WO2025134078A1 (en) 2023-12-22 2025-06-26 Suven Life Sciences Limited Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)
TW202525292A (zh) * 2023-12-27 2025-07-01 大陸商宜昌人福藥業有限責任公司 稠合嘧啶環化合物、藥物組合物及其應用
WO2025145091A1 (en) 2023-12-29 2025-07-03 Pfizer Inc. Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases
WO2025201078A1 (zh) * 2024-03-25 2025-10-02 四川科伦药物研究院有限公司 化合物、包含其的药物组合物及其制备方法和用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994017197A1 (fr) 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
NZ337765A (en) 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
SI1257584T2 (sl) 2000-02-24 2013-07-31 Washington University St. Louis Humanizirana protitelesa, ki veĹľejo amiloidni peptid beta
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
CA2427661C (en) 2000-11-03 2013-05-28 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
US20040192898A1 (en) 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
BR0315157A (pt) 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
EP1638935A1 (en) 2003-06-19 2006-03-29 Pfizer Products Inc. Nk1 antagonist
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
BRPI0507374A (pt) 2004-02-02 2007-07-10 Pfizer Prod Inc moduladores do receptor de histamina-3
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
MX2007004794A (es) 2004-10-25 2007-07-09 Lilly Co Eli Tienopiridinas como potenciadores alostericos del receptor muscarinico m4.
US20090074775A1 (en) 2004-12-22 2009-03-19 David Michael Holtzman Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
US8227475B2 (en) 2005-05-12 2012-07-24 Pfizer Inc. Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126081A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
US7812040B2 (en) 2005-06-22 2010-10-12 Pfizer Inc. Histamine-3 receptor antagonists
TW200713011A (en) 2005-09-30 2007-04-01 Hon Hai Prec Ind Co Ltd System, method and electrical apparatus for data transferring
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
HRP20110539T1 (hr) 2006-04-21 2011-08-31 Pfizer Products Inc. PIRIDINO[3,4-b]PIRAZINONI
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
CN1869036A (zh) * 2006-06-30 2006-11-29 中国药科大学 7－取代－3－氯吡咯并[3,4－b]吡啶化合物
CA2676456C (en) 2007-01-22 2012-03-27 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
WO2012047702A1 (en) 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
AR083855A1 (es) 2010-11-15 2013-03-27 Abbott Lab Inhibidores de nampt y rock
AU2012240122B2 (en) * 2011-04-08 2016-08-25 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
EP2712655B1 (en) * 2011-04-28 2019-12-18 The Broad Institute, Inc. Inhibitors of histone deacetylase
US9018224B2 (en) * 2011-11-15 2015-04-28 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
US8741892B2 (en) * 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
WO2013126856A1 (en) 2012-02-23 2013-08-29 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2014035829A1 (en) 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators
WO2015027214A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
US20160200733A1 (en) * 2013-08-23 2016-07-14 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
JP6479029B2 (ja) * 2014-02-06 2019-03-06 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１受容体アゴニストとしての二環式アザ化合物
WO2015140614A1 (en) 2014-03-21 2015-09-24 Align Technology, Inc. Segmented orthodontic appliance with elastics

Also Published As

Publication number Publication date
WO2018002760A1 (en) 2018-01-04
HUE054857T2 (hu) 2021-10-28
CA2972070A1 (en) 2018-01-01
US11905284B2 (en) 2024-02-20
MX2019000231A (es) 2019-08-29
SG11201811712QA (en) 2019-01-30
BR112018077257A2 (pt) 2019-04-02
PT3478679T (pt) 2021-06-30
TW201811780A (zh) 2018-04-01
TWI736642B (zh) 2021-08-21
PL3478679T3 (pl) 2021-10-25
ZA201900519B (en) 2022-07-27
DK3478679T3 (da) 2021-06-21
US20200207762A1 (en) 2020-07-02
US20210309659A1 (en) 2021-10-07
US10604519B2 (en) 2020-03-31
EP3872078A1 (en) 2021-09-01
ES2878160T3 (es) 2021-11-18
KR20190035713A (ko) 2019-04-03
US20230192690A1 (en) 2023-06-22
KR102470497B1 (ko) 2022-11-23
IL263912B (en) 2022-04-01
JP7046018B2 (ja) 2022-04-01
PH12019500004A1 (en) 2019-10-21
CN109641898A (zh) 2019-04-16
EP3478679A1 (en) 2019-05-08
JP2019519583A (ja) 2019-07-11
IL263912A (en) 2019-01-31
AU2017286868A1 (en) 2019-02-21
UY37311A (es) 2018-01-31
EP3478679B1 (en) 2021-04-21
MX386258B (es) 2025-03-18
US20180002331A1 (en) 2018-01-04
US20240190869A1 (en) 2024-06-13
AU2017286868B2 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
CN109641898B (zh) 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物
EP3642202B1 (en) Dihydro-pyrrolo-pyridine derivatives
TWI801540B (zh) 哌嗪氮雜螺衍生物
HK40058715A (en) 5,7-dihydro-pyrrolo-pyridine derivatives for use in the treament of depression, anxiety or panic disorders
HK40099374A (en) Piperazine azaspiro derivatives
EA044379B1 (ru) Производные 5,7-дигидропирролопиридина
HK40008377B (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
HK40044050A (en) Piperazine azaspiro derivaves
BR112018077257B1 (pt) Compostos derivados de 5,7-di-hidro-pirrolo-piridina, composição farmacêutica e seus usos para o tratamento de doenças neurológicas e neurodegenerativas
HK40027521A (en) Dihydro-pyrrolo-pyridine derivatives
BR122024018838A2 (pt) Derivados de 5,7-di-hidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas, composição farmacêutica, kit e seus usos
HK40045213B (en) Piperazine azaspiro derivaves
HK40027664B (en) Dihydro-pyrrolo-pyridine derivatives
HK40027664A (en) Dihydro-pyrrolo-pyridine derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40007595

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant